LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
-7.46%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$699M
AUM Growth
+$699M
(-18%)
Cap. Flow
-$58.8M
Cap. Flow
% of AUM
-8.41%
Top 10 Holdings %
Top 10 Hldgs %
51.76%
Holding
52
New
12
Increased
5
Reduced
17
Closed
9
Top Buys
| 1 |
Biogen
BIIB
|
$27.8M |
| 2 |
Neurocrine Biosciences
NBIX
|
$20.2M |
| 3 |
Ascendis Pharma
ASND
|
$16.1M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$14.6M |
| 5 |
Galapagos
GLPG
|
$13.5M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$36.3M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
$20.7M |
| 3 |
BCYC
Bicycle Therapeutics
BCYC
|
$14.6M |
| 4 |
Fulcrum Therapeutics
FULC
|
$14.6M |
| 5 |
Ventyx Biosciences
VTYX
|
$13M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $52.8M | 7.55% | 800,000 -550,000 | -41% | -$36.3M |
|
2
IDEAYA Biosciences
IDYA
$2.15B
| $49.4M | 7.07% | 3,600,000 -300,000 | -8% | -$4.12M |
|
3
Cytokinetics
CYTK
$4.23B
| $44M | 6.3% | 1,250,000 -250,000 | -17% | -$8.8M |
|
4
Immunovant
IMVT
$2.56B
| $38.8M | 5.55% | 2,500,000 -650,000 | -21% | -$10.1M |
|
|
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $37M | 5.29% | 1,520,000 +20,000 | +1% | +$487K |
|
6
Xenon Pharmaceuticals
XENE
$2.98B
| $32.2M | 4.61% | 900,000 | – | – |
|
7
Sarepta Therapeutics
SRPT
$1.78B
| $30.3M | 4.34% | 220,000 | – | – |
|
|
8
Biogen
BIIB
$19.4B
| $27.8M | 3.98% | +100,000 | New | +$27.8M |
|
9
Immunocore
IMCR
$1.62B
| $24.7M | 3.54% | 500,000 | – | – |
|
|
ALLK
10
DELISTED
Allakos
ALLK
| $24.6M | 3.53% | 5,536,666 +250,000 | +5% | +$1.11M |
|
11
Viridian Therapeutics
VRDN
$1.5B
| $24.2M | 3.46% | 950,000 -50,000 | -5% | -$1.27M |
|
|
12
Neurocrine Biosciences
NBIX
$13.8B
| $20.2M | 2.9% | +200,000 | New | +$20.2M |
|
13
Dyne Therapeutics
DYN
$1.92B
| $19.6M | 2.8% | 1,700,000 -450,000 | -21% | -$5.18M |
|
|
KRTX
14
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $18.2M | 2.6% | 100,000 -50,000 | -33% | -$9.08M |
|
15
Design Therapeutics
DSGN
$315M
| $16.1M | 2.31% | 2,797,501 | – | – |
|
|
16
Ascendis Pharma
ASND
$11.8B
| $16.1M | 2.3% | +150,000 | New | +$16.1M |
|
|
BCYC
17
Bicycle Therapeutics
BCYC
$511M
| $16M | 2.28% | 750,000 -685,000 | -48% | -$14.6M |
|
18
Rocket Pharmaceuticals
RCKT
$354M
| $15.4M | 2.21% | 900,000 +150,000 | +20% | +$2.57M |
|
19
Akero Therapeutics
AKRO
$3.74B
| $15.3M | 2.19% | 400,000 | – | – |
|
|
20
BioMarin Pharmaceuticals
BMRN
$11.2B
| $14.6M | 2.09% | +150,000 | New | +$14.6M |
|
21
Astria Therapeutics
ATXS
$349M
| $13.9M | 1.99% | 1,044,960 +180,000 | +21% | +$2.39M |
|
|
22
Galapagos
GLPG
$2.07B
| $13.5M | 1.94% | +350,000 | New | +$13.5M |
|
23
Olema Pharmaceuticals
OLMA
$375M
| $13M | 1.86% | 3,743,875 | – | – |
|
24
Madrigal Pharmaceuticals
MDGL
$9.76B
| $12.1M | 1.73% | 50,000 -10,000 | -17% | -$2.42M |
|
|
DICE
25
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $11.7M | 1.68% | 410,000 -250,000 | -38% | -$7.16M |
|